New hope for Hard-to-Treat thyroid cancer: experimental drug shows promise
NCT ID NCT05745363
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested an experimental drug called AL2846 in 33 people with a type of thyroid cancer that no longer responds to standard treatments. The goal was to see if the drug could shrink tumors or slow the cancer's growth. Participants took the drug by mouth, and doctors monitored their response and any side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFERENTIATED THYROID CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Affiliated Hospital Of Guilin Medical University
Guilin, Guangxi, 541001, China
-
Hunan Cancer Hospital
Changsha, Hunan, 410013, China
-
Jiangxi Cancer Hospital
Nanchang, Jiangxi, 330029, China
-
Yunnan Cancer Hospital
Kunming, Yunnan, 650011, China